一、持续督导工作情况 中国国际金融股份有限公司 关于上海微创心脉医疗科技（集团）股份有限公司 2025 年半年度持续督导跟踪报告 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）根据《证 券发行上市保荐业务管理办法》、《上海证券交易所科创板股票上市规则》和《上 海证券交易所上市公司自律监管指引第 11 号——持续督导》等相关规定对上海微 创心脉医疗科技（集团）股份有限公司（以下简称"心脉医疗"、"公司"或"上 市公司"）进行持续督导，针对心脉医疗 2025 年 1 月 1 日至 2025 年 6 月 30 日（以 下简称"报告期"）经营情况，出具本持续督导半年度跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对具体的持 | 保荐机构已建立并有效执 | | | | 行了持续督导制度，并制定 | | | 续督导工作制定相应的工作计划 | 了相应的工作计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始前，与上 | 保荐机构已与公司签订《保 | | | | 荐协议》，该协议明确了双 | | ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook based on revenue growth and product pipeline developments [1][3]. Core Viewpoints - The company reported a total revenue of 714 million yuan for the first half of 2025, a year-over-year decrease of 9.24%, with a net profit of 315 million yuan, down 22.03% year-over-year [1][3]. - The revenue from peripheral vascular products increased significantly by 188.57% year-over-year, driven by new product launches [3]. - The overseas revenue reached 123 million yuan, reflecting a growth of 77.05% year-over-year, attributed to the consolidation of Lombard and expanded market reach [3]. - The company has a robust product pipeline with several new products approved and in various stages of clinical trials, which is expected to drive future growth [3]. Financial Summary - For 2025, the company is projected to achieve revenues of 1.454 billion yuan, with a year-over-year growth rate of 20.5% [4]. - The net profit for 2025 is estimated at 607 million yuan, representing a growth of 20.8% year-over-year [4]. - The gross margin is expected to decline slightly from 76.5% in 2023 to 69.9% in 2025 [4]. - The earnings per share (EPS) is projected to increase from 3.99 yuan in 2023 to 4.92 yuan in 2025 [4].

Group 1 - The core viewpoint of the news is that Xinmai Medical's stock has seen a rise of 5.34%, reaching a price of 112.50 CNY per share, with a total market capitalization of 13.867 billion CNY [1] - Xinmai Medical, established on August 17, 2012, specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with 71.94% of its revenue coming from aortic products and 28.04% from peripheral and other products [1] - The trading volume for Xinmai Medical was 1.33 billion CNY, with a turnover rate of 0.98% [1] Group 2 - According to data, Bosera Fund's ETF, which is among the top ten circulating shareholders of Xinmai Medical, reduced its holdings by 16,300 shares in the second quarter, now holding 524,800 shares, representing 0.43% of the circulating shares [2] - The Bosera Science and Technology Innovation Board 100 ETF Link A (019857) has achieved a year-to-date return of 40.62% and a one-year return of 84.94%, ranking 603 out of 4222 and 516 out of 3795 respectively [2] - The fund manager of Bosera's ETF is Tang Yibing, who has been in the position for 3 years and has overseen a total fund asset size of 9.874 billion CNY [3]

Group 1 - The core viewpoint of the report is that Xinpai Medical (688016.SH) is rated as a buy due to its promising growth prospects and strong revenue performance [1] - The company has shown significant progress in research and development, indicating a solid reserve of growth momentum for the future [1] - Xinpai Medical's revenue nearly doubled year-on-year in the first half of the year, reflecting successful international expansion [1] - The gross profit margin has been affected by product price reductions and increased expenses [1] Group 2 - The report highlights potential risks including price reduction from centralized procurement, slow bidding process, and underperformance in consumable promotion [1]

Core Viewpoint - The company, Xinmai Medical, has shown significant growth in revenue and profit, with a focus on expanding its product offerings and international market presence. Financial Performance - For the reporting period, the company achieved operating revenue of 714 million yuan and a net profit attributable to shareholders of 315 million yuan, with basic earnings per share of 2.55 yuan [1][4] - The company plans to distribute a cash dividend of 13.00 yuan per 10 shares, totaling 157 million yuan [1] Product Development and Approvals - Several products have made breakthroughs in the first half of 2025, including the Cratos branched aortic stent system, which has been approved for clinical use in China [1] - The company has a total of 31 products available globally, with 5 receiving CE certification and 9 entering special review procedures for innovative medical devices in China [2] Market Expansion - The Cratos branched stent is priced under 100,000 yuan and has exceeded promotional expectations, with clinical studies initiated in Europe [3] - Overseas revenue has increased by over 95% year-on-year, accounting for 17% of total sales, driven by the integration of Lombard data and growth in international markets [3][4] Share Buyback Program - The company is conducting a second phase of share repurchase, with a budget of 100 million to 200 million yuan, aimed at employee stock ownership plans or equity incentives [5] - As of August 31, 2025, the company has repurchased 1,228,743 shares, representing 1.00% of total share capital, with a total expenditure of approximately 129 million yuan [5]

Industry Overview - In 2022, the structure of the upstream materials in China's biomedical materials industry showed a high proportion of metal and polymer materials. By 2024, composite materials and bio-derived materials are expected to gain market share due to advancements in 3D printing technology and increased demand in the medical aesthetics sector, while metal materials, polymer materials, and medical ceramics may see slight declines in market share due to substitution effects and market competition [1][2]. Competitive Landscape - The competitive landscape of the biomedical materials industry can be divided into three tiers based on revenue: - Tier 1 companies have revenues exceeding 2 billion yuan, including companies like Lepu Medical, Haohai Biological, and Dabo Medical. - Tier 2 companies have revenues between 1 billion and 2 billion yuan, represented by Weigao Orthopedics, Xinmai Medical, and Blue Sail Medical. - Tier 3 companies have revenues below 1 billion yuan, including Guoci Materials, Bairen Medical, and Zhenghai Biological [3][6]. Business Layout Comparison - Companies such as Aojing Medical, Weigao Orthopedics, and Haohai Biological derive nearly 100% of their revenue from biomedical materials, while others have a relatively low proportion of revenue from this segment [5][6]. Business Planning and Innovation - The business planning in the biomedical materials sector is characterized by diversification, focusing on technological innovation, market expansion, and industry chain integration. Leading companies are investing in R&D and international expansion, while smaller firms are seeking breakthroughs through differentiated technologies such as regenerative medicine and 3D printing. Future competitive cores are expected to revolve around biodegradable materials, smart devices, and precision medicine [7][9]. Company-Specific Strategies - Guoci Materials focuses on new material platforms, achieving a 70% market share in nano-alumina materials for dental implants and high-end aesthetic restorations, with products entering over 20 countries [9]. - Aojing Medical specializes in regenerative repair implants, with products widely used in various surgical fields and a strong international market presence [9]. - Weigao Orthopedics is adjusting its business model to address procurement policies and is expanding into new fields such as minimally invasive spine and arthroscopic surgery [10]. - Lepu Medical's core business is cardiovascular intervention materials, with products like the NeoVas bioabsorbable stent and MemoSorb® fully degradable occluders [10]. - Xinmai Medical is focusing on drug-coated stents and has entered special review channels for innovative medical devices [10]. Revenue and Market Share Insights - The revenue of key companies in the biomedical materials sector varies significantly, with Weigao Orthopedics reporting 14.51 billion yuan from its orthopedic materials, representing 100% of its total revenue [6]. - Lepu Medical generated 33.27 billion yuan from cardiovascular system materials, accounting for 54.51% of its total revenue [6]. Future Trends - The industry is expected to see increased emphasis on biodegradable materials and smart medical devices, driven by policy support and technological advancements [7].

Group 1: Company Insights - E Fund recently conducted research on seven listed companies, highlighting significant growth in revenue for Yuanjie Technology, particularly in the demand for 400G/800G optical modules, with expectations for substantial growth in the second half of 2025 [1] - Weisi Medical's lower limb exoskeleton device has been included in the medical insurance directory, and its electrical stimulation products are primarily used in obstetrics and gynecology departments [1] - Dekoli experienced rapid growth in computing power demand but faced challenges with capacity and supply chain resources, leading to insufficient order fulfillment [1] - Ningbo Jingda's performance was slightly impacted by international trade factors, but it saw a double-digit growth in orders in the second quarter, with a 70% increase in export orders after acquiring Wuxi Micro Research [2] - Xinmai Medical reported a revenue of 714 million yuan and a net profit of 315 million yuan, with overseas revenue growing over 95% [3] - Kehua Data achieved a revenue of 3.733 billion yuan, with a 0.06% year-on-year growth, and a 16.77% increase in data center business revenue [4] Group 2: Industry Trends - The demand for high-power CW light sources and high-speed EML technology is increasing, with companies focusing on core technology breakthroughs and maintaining high gross profit margins [1] - The integration of advanced technologies in manufacturing, such as high-frequency pipe-making and rolling machines, is being pursued to promote import substitution in the industry [2] - The development of new energy solutions, including 2000V450kW inverters, is being accelerated to serve various sectors, including state-owned enterprises [3] - The semiconductor industry is facing challenges with high R&D investments and increased financial costs, impacting profitability for companies like Dongxin [5]

Group 1: Company Insights - Yuanjie Technology reported significant revenue growth in the data communication sector, particularly for 400G/800G optical modules, with expectations for substantial growth in the second half of 2025 [1] - Huafeng Measurement Control experienced a 41% year-on-year revenue increase in the semiconductor industry, with a notable 37.6% growth in net profit, driven by stable demand in power devices and consumer electronics [2] - Dekeli faced challenges in order delivery due to insufficient capacity and supply chain resources, but anticipates improvement with new facilities coming online in the second half of 2025 [3] - Kebo Da achieved a revenue of 3.047 billion yuan, an 11.1% increase year-on-year, with a net profit of 451 million yuan, reflecting a 21.34% growth [4] - Ningbo Jingda's performance was slightly impacted by international trade factors, but saw a recovery in the second quarter with a 70% increase in export orders [5] - Jinbo Co. reported a 19.69% increase in revenue to 411 million yuan, with significant growth in new business areas, particularly in the lithium battery sector [6] - Xinmai Medical achieved a revenue of 714 million yuan and a net profit of 315 million yuan, with overseas revenue growing over 95% [7] - Guangxun Technology's revenue is expected to continue growing, with a historical peak in silicon optical module shipments and plans to adjust production capacity based on market demand [8] Group 2: Industry Trends - The semiconductor industry is expected to continue its recovery trend into 2025, with increasing demand for data centers and power devices [2] - The demand for optical communication products is anticipated to grow, particularly with the introduction of 400G and 800G technologies [1][8] - The automotive sector is seeing a shift towards energy management products and lightweight solutions, with companies exploring new directions in EV and hydrogen energy [5] - The overall market for optical communication is projected to remain stable in the second half of 2025, with a focus on MEMS technology for OCS products [8]

Group 1 - The core viewpoint of the news is that Hengsheng Qianhai Fund has conducted research on a listed company, focusing on its financial performance and product developments [1] - The company, Xinmai Medical, reported a revenue of 714 million yuan and a net profit of 315 million yuan during the reporting period [1] - The company plans to distribute a cash dividend of 1.57 billion yuan, which is 13.00 yuan per 10 shares (including tax) [1] - The product Cratos was launched domestically in March with a listing price below 100,000 yuan, and its promotion progress has exceeded expectations [1] - Hector has received a custom certificate from the EU and has completed clinical implants in multiple European countries, gaining recognition from doctors [1] - The company's R&D investment is expected to be around 10% this year, with a future target of maintaining it between 10% and 15% [1] - Overseas revenue has increased by over 95% year-on-year, accounting for 17% of total revenue, primarily due to the consolidation of Lombard and organic growth, covering 45 countries with plans to expand to 60 countries next year [1] - High-margin products such as Talos, Cratos, and Fontus are set to be launched internationally [1] Group 2 - Hengsheng Qianhai Fund was established in 2016 and currently has an asset management scale of 16.47 billion yuan, ranking 126 out of 210 [2] - The fund's asset management scale for non-monetary public funds is 16.468 billion yuan, ranking 109 out of 210 [2] - The fund manages 54 public funds, ranking 100 out of 210, with 7 fund managers, ranking 126 out of 210 [2] - The best-performing public fund product in the past year is Hengsheng Qianhai High-end Manufacturing Mixed A, with a latest net value of 0.96 and a growth of 89.37% over the past year [2] - The latest public fund product raised by the fund is Hengsheng Qianhai Ruifeng Mixed A, which is a mixed-type equity fund, with a concentrated subscription period from August 18, 2025, to September 5, 2025 [2]

Group 1: Company Insights - Hongde Fund recently conducted research on six listed companies, including Haitai Technology, which has launched its second factory in Thailand, expected to generate an additional annual output value of approximately 100 million yuan [1] - Zhongcai International is the only company in the global cement technology equipment and engineering service market with a complete industrial chain, maintaining good cooperation with Tibetan cement enterprises [2] - Dekeli anticipates rapid growth in computing power demand by the first half of 2025, but faces challenges in capacity and supply chain resources, leading to insufficient order delivery [3] - Kebo Da achieved a revenue of 3.047 billion yuan in the first half of 2025, a year-on-year increase of 11.10%, with a net profit of 451 million yuan, up 21.34% [4] - Jinbo Co. reported a revenue of 411 million yuan in the first half of 2025, a year-on-year growth of 19.69%, with significant growth in the transportation and lithium battery sectors [5] - Xinmai Medical achieved a revenue of 714 million yuan and a net profit of 315 million yuan, with overseas revenue growing over 95% [6] Group 2: Financial Performance - Haitai Technology's modified materials, such as PEEK-CF50, are being developed for a leading humanoid robot company, although they have not yet entered the supply chain [1] - Zhongcai International has completed the localization of DeepSeek, providing large model applications and opening enterprise knowledge base scenarios [2] - Dekeli's telecom business saw a year-on-year decline of approximately 8%, but new factory operations are expected to improve performance in the second half of the year [3] - Kebo Da's main business revenue was 2.948 billion yuan, with domestic sales accounting for 1.801 billion yuan and international sales 1.148 billion yuan [4] - Jinbo Co. has completed the carbon-ceramic brake disc project and is advancing the customer validation of porous carbon products [5] - Xinmai Medical plans to maintain R&D investment at 10%-15% in the future, with high-margin products set to be launched internationally [6]